Antengene Receives Australian HREC Green Light for Phase I “ATTRACT” Trial of Bispecific Antibody ATG-201

Bulletin Express

10 hours ago

Antengene Corporation Limited announced that its proprietary CD19/CD3 bispecific T-cell engager, ATG-201, has secured Human Research Ethics Committee (HREC) approval in Australia for the Phase I ATTRACT clinical study targeting B cell-related autoimmune diseases. The study has also completed the Clinical Trial Notification procedure with the Therapeutic Goods Administration.

Management notes that ATG-201 remains in early-stage development and may not ultimately achieve commercialisation success. Investors are advised to exercise caution when dealing in the company’s securities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1170772290"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1170772290\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1170772290?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-25 06:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170772290","market":"us","top_or_hot":-1,"title":"Antengene Receives Australian HREC Green Light for Phase I “ATTRACT” Trial of Bispecific Antibody ATG-201","media":"Bulletin Express","content":"<p>Antengene Corporation Limited announced that its proprietary CD19/CD3 bispecific T-cell engager, ATG-201, has secured Human Research Ethics Committee (HREC) approval in Australia for the Phase I ATTRACT clinical study targeting B cell-related autoimmune diseases. The study has also completed the Clinical Trial Notification procedure with the Therapeutic Goods Administration.</p>\n<p>Management notes that ATG-201 remains in early-stage development and may not ultimately achieve commercialisation success. Investors are advised to exercise caution when dealing in the company’s securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Antengene Receives Australian HREC Green Light for Phase I “ATTRACT” Trial of Bispecific Antibody ATG-201</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAntengene Receives Australian HREC Green Light for Phase I “ATTRACT” Trial of Bispecific Antibody ATG-201\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-25 06:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Antengene Corporation Limited announced that its proprietary CD19/CD3 bispecific T-cell engager, ATG-201, has secured Human Research Ethics Committee (HREC) approval in Australia for the Phase I ATTRACT clinical study targeting B cell-related autoimmune diseases. The study has also completed the Clinical Trial Notification procedure with the Therapeutic Goods Administration.</p>\n<p>Management notes that ATG-201 remains in early-stage development and may not ultimately achieve commercialisation success. Investors are advised to exercise caution when dealing in the company’s securities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06996","symbol_name":"德琪医药-B","start_time":0,"source_url":"","article_id":"1170772290","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170772290","pubTimestamp":1787611595,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Antengene Corporation Limited announced that its proprietary CD19/CD3 bispecific T-cell engager, ATG-201, has secured Human Research Ethics Committee (HREC) approval in Australia for the Phase I...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06996":"德琪医药-B"},"translate_title":"Antengene公司获得澳大利亚HREC批准，开展双特异性抗体ATG-201的I期“ATTRACT”试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06996":1},"content_text":"Antengene Corporation Limited announced that its proprietary CD19/CD3 bispecific T-cell engager, ATG-201, has secured Human Research Ethics Committee (HREC) approval in Australia for the Phase I ATTRACT clinical study targeting B cell-related autoimmune diseases. The study has also completed the Clinical Trial Notification procedure with the Therapeutic Goods Administration.\nManagement notes that ATG-201 remains in early-stage development and may not ultimately achieve commercialisation success. Investors are advised to exercise caution when dealing in the company’s securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"executive,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}